Asset Details
Do you wish to reserve the book?
Personalized medicine: the enabling role of nanotechnology
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Personalized medicine: the enabling role of nanotechnology
Do you wish to request the book?
Personalized medicine: the enabling role of nanotechnology
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Personalized medicine: the enabling role of nanotechnology
2016
Overview
[...]these very same medications are the drugs that reach blockbuster status and bring the revenue that is so vital for a filled drug development pipeline and thus are critical for a healthy pharmaceutical industry. While the slow adoption of new antibiotics may be appropriate for public health maximization to delay development of resistance, it is the key factor that drives the poor economics for companies. [...]tailored drugs are only useful if tailored diagnostics can identify appropriate patients, hence posing dual burdens of large, expensive clinical trials and diminished revenue potential on pharmaceutical industry (3). Technological solutions for the accelerated discovery of biomarkers, the engineering of improved drug carriers, the development of point-of-care diagnostic tests and monitoring devices, and appropriate data management approaches may turn precision medicine into profitable endeavors for all parties involved (7). Currently, the US FDA records a 95% failure rate for drug approval due to safety and efficacy issues; hence, there is an urgent need to reduce the risk for pharmaceutical industry and patients and make both drug development and use safer.
